Global Dilated Cardiomyopathy Market, By Drug class (Angiotensin-converting enzyme (ACE) Inhibitors, Beta-blockers, Aldosterone antagonists, Angiotensin II Receptor Blockers, Others), Treatment Type (Medication, Implantable Devices, Heart Pumps, Cardioverter-Defibrillators, Others), Route of Administration (Oral, Parenteral, Others), End-User (Hospitals, Research Institutes, Specialty Clinics), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others) – Industry Trends and Forecast to 2029.
Dilated Cardiomyopathy Market Analysis and Size
The global dilated cardiomyopathy market is expected to witness significant growth during the forecast period. There were around 2.5 million dilated cardiomyopathy prevalent cases. According to the Pediatric Cardiomyopathy Registry, dilated cardiomyopathy occurs at a rate of 6 per million children. It is usually diagnosed in younger children with an average age of diagnosis at 2 years. Common symptoms include fatigue, edema in ankles, feet, legs, veins in the neck and abdomen. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global dilated cardiomyopathy market in the forecast period 2022-2029. The expected CAGR of global dilated cardiomyopathy market is tend to be around 4% in the mentioned forecast period. The market was valued at USD 328.8 million in 2021, and it would grow upto USD 450 million by 2029. The global dilated cardiomyopathy market is tend to have a healthy CAGR in the mentioned forecast period. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Dilated cardiomyopathy is a term given to the heart muscle diseases and is considered a fatal cardiac disorder. It is usually typically characterised by left and right ventricular dilation and reduced myocardial contractility. A common cause of heart failure is the incompetence of the heart to supply the body with enough blood, and dilated cardiomyopathy also contributes to factors such as irregular heartbeats, blood clots, or sudden death. People of all age groups are affected by dilated cardiomyopathy, which includes infants and children, but it is most common in men ages 20 to 50. This diseased condition is increasing and thus it is very important to the healthcare sector.
Dilated Cardiomyopathy Market Scope and Segmentation
2022 to 2029
2020 (Customizable to 2014 - 2019)
Revenue in USD Million, Volumes in Units, Pricing in USD
Drug class (Angiotensin-converting enzyme (ACE) Inhibitors, Beta-blockers, Aldosterone antagonists, Angiotensin II Receptor Blockers, Others), Treatment Type (Medication, Implantable Devices, Heart Pumps, Cardioverter-Defibrillators, Others), Route of Administration (Oral, Parenteral, Others),End-User (Hospitals, Research Institutes, Specialty Clinics), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others)
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
Market Players Covered
Alexion Pharmaceuticals, Inc. (U.S.), Sanofi (France), Takeda Pharmaceutical Company Limited (Japan), Vertex Pharmaceuticals Incorporated (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Abbott (U.S.), Amgen Inc. (U.S.), Jazz Pharmaceuticals, Inc. (U.K.), Pfizer Inc (U.S.), PerkinElmer Inc (U.S.), Bio-Rad Laboratories, Inc. (U.S.)
Global Dilated Cardiomyopathy Market Dynamics
- Increase in Diagnostic Tests
Different diagnostic tests used to treat peripartum cardiomyopathy market are boosting the market growth. Multiple tests such as electrocardiography, cardiac MRI to detect the presence of specific defects. Thus, it acts as a major driver in the market growth.
- Increasing Prevalence of Ischemic Heart Disease
According to WHO statistics for the year 2020, ischemic heart disease accounts for 16% of all fatalities globally. As per the February 2020 article titled "Heart failure (HF) in France: Chronic Heart Failure Therapeutic Management and Risk of Cardiac Decompensation in Real-Life Setting," about 1 million people in France would be affected by heart failure. Despite well-defined treatment management, there are approximately 70,000 heart failure-related deaths and more than 150,000 hospitalizations. This boosts the market growth.
- Increase in Smoking and Lifestyle Changes
Cigarette smoking is one of the leading cause of preventable disease and death in the U.S. It accounts for more than 480,000 deaths every year. In addition to this, the lifestyle changes that are attained by today’s population such as unhealthy lifestyle, poor diet, stress and many such factors altogether contribute to the developing opportunities of the market.
- Increase in the number of research and development activities
The market's growth is boosted by an increase in the number of R&D activities. This will provide beneficial opportunities for the global dilated cardiomyopathy market. To motivate researchers and pharmaceutical companies to develop novel medicines, the government is funding research and development (R&D) initiatives. For instance, ARRY-371797, also known as ARRY-797, is an oral, p38 mitogen-activated protein kinase (MAPK) inhibitor discovered by Array scientists. It is under phase III trial for the treatment of patients suffering from dilated cardiomyopathy due to a Lamin A/C gene mutation. In 2019, Pfizer acquired Array Biopharma to expand its pipeline. This drug is in phase III pipeline drugs of Pfizer under the name PF-07265803 for treating patients affected by dilated cardiomyopathy.
- Lack of skilled professionals
The lack of qualified personnel who are unable to perform these treatments could limit the growth of the global dilated cardiomyopathy market over a forecast period.
- High Cost
The huge expenditure required for the treatment processes surely hamper the market growth. Several market players make huge investment in installing new and advanced treatment procedures to faster the recovery process and in return the cost is increased.
This global dilated cardiomyopathy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global peripartum cardiomyopathy market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Dilated Cardiomyopathy Market
COVID-19 has left a major global public health crisis that has impacted practically every market sector. Its long-term consequences are expected to boost the industry growth during the forecast period.
The load on healthcare facilities and professionals was increasing with the rapid surge in patient numbers. Many hospitals have decided to cancel or postpone procedures. The pandemic had a mixed influence on the dilated cardiomyopathy market. The pandemic has put a strain on the treatment procedures in general. As a result of the lockdown and travel restrictions, the number of hospitals has decreased and countless drives have been cancelled around the world.
- In August 2019, MyoKardia, Inc., launched the 2nd Annual Myoseeds Research Grant Program to promote independent biology research and understand the mechanism of cardiomyopathies and its associated treatment.
- In 2019, the DCM Foundation in Ohio announced the launch of a website to raise awareness for dilated cardiomyopathy (DCM) and educate the patients to manage the heart condition. Many causes of DCM have been reported and around 1 in 250 people have DCM. Most of the patients have been reported to suffer from Idiopathic DCM. Therefore, genetic factors are considered to play a major role in idiopathic DCM. Henceforth, in order to find this relation, DCM foundation has collaborated with DCM Research Project which is funded by National Institute of Health (NIH).
Global Dilated Cardiomyopathy Market Scope
The global peripartum cardiomyopathy market is segmented on the basis of drug class, treatment type, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
- Angiotensin-converting enzyme (ACE) Inhibitors
- Aldosterone antagonists,
- Angiotensin II Receptor Blockers
- Implantable Devices
- Heart Pumps
Route of Administrtaion
- Research Institutes
- Specialty Clinics
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacies
Dilated Cardiomyopathy Market Regional Analysis/Insights
The global dilated cardiomyopathy market is analysed and market size insights and trends are provided by diagnosis, distribution channel and end-user as referenced above.
The major countries covered in the global dilated cardiomyopathy market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the market in the forecast period due to the global leaders in research and development activities, high incidence of heart diseases and the presence of refined medical facilities.
Asia-Pacific is expected to grow during the forecast period due to the developing healthcare facilities, large number of generic manufacturers and rise in government initiatives and specialist communities.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Dilated Cardiomyopathy Market Share Analysis
The global dilated cardiomyopathy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global dilated cardiomyopathy market
Key players operating in the global dilated cardiomyopathy market include:
- Alexion Pharmaceuticals, Inc. (U.S.)
- Sanofi (France)
- Takeda Pharmaceutical Company Limited (Japan)
- Vertex Pharmaceuticals Incorporated (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Abbott (U.S.)
- Amgen Inc. (U.S.)
- Jazz Pharmaceuticals, Inc. (U.K.)
- Pfizer Inc (U.S.)
- PerkinElmer Inc (U.S.)
- Bio-Rad Laboratories, Inc. (U.S.)